The News
Antiverse has raised $9.3 million in a Series A funding round to develop antibodies targeting diseases previously deemed undruggable. The company has also entered a research agreement with the Cystic Fibrosis Foundation to further its efforts.
Why It Matters
The funding will be utilized to accelerate Antiverse's internal pipeline and advance its lead antibody programs towards in vivo efficacy studies. The company employs an AI-driven, lab-in-the-loop platform to design, build, and validate therapeutic-strength antibodies.
Key Evidence
The funding amount is $9.3 million, and the partnership with the Cystic Fibrosis Foundation highlights the credibility and potential impact of Antiverse's research.
Source
finanznachrichten
DE source 路 Published 5d ago